{"id":"W2166918329","doi":"10.1056/nejmoa1405095","title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3031,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"Cliniques Universitaires Saint-Luc; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of California, Davis; Duke Cancer Institute; Astellas Pharma Global Development; Weill Cornell Medical College; Rigshospitalet; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Institut Gustave-Roussy; Astellas Pharma; Université de Montréal; University of Washington; University of Alberta; Memorial Sloan-Kettering Cancer Center; Monash University; Oregon Health and Science University","keywords":"Enzalutamide; Prostate cancer; Medicine; Oncology; Chemotherapy; Internal medicine; Docetaxel; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}